GlassScriptPhysician profile
Anthony W Stephens
NPI 1659344117
$19,850.83
in general payments reported to CMS, 2019-2025
26 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2021: $623 · 2022: $2,896 · 2023: $143 · 2024: $103 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249 · Long Term Medical Supply Or Device Loan: $83.33 · Education: $45.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.33 |
| Long Term Medical Supply Or Device Loan | $83.33 |
| Education | $45.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13,809.98 | 2019-2022 | |
| Tosoh Bioscience, INC. | $1,918.00 | 2019 | |
| Beigene USA, INC. | $1,350.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,185.00 | 2019-2023 | |
| Celgene Corporation | $631.27 | 2019-2022 | |
| Intuitive Surgical, INC. | $192.37 | 2023-2025 | Da Vinci Surgical System |
| Amgen INC. | $118.67 | 2019 | |
| Janssen Biotech, INC. | $97.14 | 2019-2024 | Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $95.17 | 2019-2024 | Enhertu |
| Genentech USA, INC. | $58.85 | 2019 | |
| Exelixis INC. | $56.51 | 2019 | |
| Merck Sharp & Dohme LLC | $46.29 | 2019 | |
| Gilead Sciences, INC. | $40.30 | 2019-2021 | |
| Pfizer INC. | $36.65 | 2019-2022 | |
| Lilly USA, LLC | $32.63 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29.50 | 2019 | |
| Eisai INC. | $27.71 | 2019 | |
| Seagen INC. | $26.45 | 2019 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Tesaro, INC. | $14.49 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.24 | 2019 | |
| Astellas Pharma US INC | $14.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2019 | |
| Puma Biotechnology, INC. | $11.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.